Лучшие больницы для «Liver Cancer Treatment» в Дубай, ОАЭ

The cost of liver cancer treatment depends significantly on the treatment modality, disease stage, hospital tier, and individual patient complexity. In India, treatment at JCI- and NABH-accredited hospitals typically ranges from $4,000 to $35,000 USD: percutaneous ablation (RFA/MWA) falls in the $4,000–$8,000 range; TACE or Y-90 TARE costs $6,000–$12,000 per session; surgical hepatic resection ranges from $8,000–$18,000; and liver transplantation (living-donor) ranges from $20,000–$35,000. In the UAE, at JCI- and DHA-licensed centers in Dubai and Abu Dhabi, equivalent treatments cost approximately 2–2.5 times higher: ablation $9,000–$18,000; TACE/Y-90 $15,000–$28,000; hepatic resection $20,000–$45,000; and liver transplantation $45,000–$75,000. These estimates typically include surgeon fees, anesthesiologist fees, hospital room charges, standard medications, and routine post-operative care but exclude international flights, accommodation, and ongoing systemic therapy drugs, which GAF Healthcare can itemize separately. Both destinations offer dramatically lower costs compared to the United States ($50,000–$300,000+) or Germany ($40,000–$200,000+) for comparable treatment. GAF Healthcare provides a detailed, itemized cost estimate within 48 hours of receiving the patient's medical records.

The fit-to-fly timeline varies directly with the treatment modality and the patient's recovery trajectory. For percutaneous ablation (RFA or MWA), patients are typically discharged within 2–3 days and are generally fit for an international flight within 3–4 weeks, allowing adequate time for wound healing, liver enzyme normalization, and the first post-treatment imaging assessment at 4–6 weeks. For TACE or Y-90 TARE, hospital discharge occurs at 3–5 days, and most patients are fit to fly within 3–5 weeks, after post-embolization syndrome resolves and initial treatment response imaging is completed. For major open or robotic hepatic resection, patients require a hospital stay of 10–18 days, followed by an additional 3–4 weeks of supervised in-country recovery — giving a total minimum stay of approximately 6–8 weeks before safe air travel. This timeline accounts for liver function stabilization, surgical wound healing, drain removal, and assessment of post-hepatectomy liver failure risk. For liver transplant recipients, the in-country stay is a minimum of 8–12 weeks due to the complexity of immunosuppression titration, rejection monitoring, and the higher risk of early post-operative complications requiring rapid access to the transplant team. All fit-to-fly clearances are issued formally in writing by the treating surgeon and hepatologist. GAF Healthcare coordinates extended accommodation and daily nurse check-ins for the full recovery period to ensure patients do not travel prematurely.

Success rates for liver cancer treatment are strongly stage-dependent and modality-specific, and must be interpreted in the context of each patient's BCLC stage, Child-Pugh liver function, and tumor biology. For early-stage HCC (BCLC Stage 0/A) treated with curative intent: surgical resection achieves a 5-year overall survival of 50–70% at high-volume centers, with recurrence-free survival of 40–60% at 5 years; percutaneous ablation achieves complete ablation rates of 90–95% for tumors ≤2 cm, with 5-year survival of 40–70%; and liver transplantation within Milan criteria achieves the best long-term outcomes, with 5-year survival exceeding 70% and a recurrence rate below 10–15%. For intermediate-stage HCC (BCLC B) treated with TACE, median overall survival is 26–30 months; objective response rates (per mRECIST) are 50–60%. Y-90 TARE demonstrates comparable efficacy with potentially superior outcomes in patients with portal vein tumor thrombus. For advanced-stage HCC (BCLC C) on first-line atezolizumab + bevacizumab (IMbrave150 data), median overall survival is approximately 19.2 months versus 13.4 months with sorafenib, with an objective response rate of 30%. These outcomes at GAF Healthcare's partner institutions in India and the UAE are achieved through high case volumes, dedicated hepatobiliary MDT boards, robotic and laparoscopic surgical expertise, and access to the full armamentarium of locoregional and systemic therapies. Regular audited outcomes data is available from partner hospitals upon request.